<DOC>
	<DOCNO>NCT02797080</DOCNO>
	<brief_summary>The purpose long term extension study evaluate long-term safety ACTIMMUNE® ( interferon-γ 1b ) participant Friedreich 's Ataxia ( FA ) .</brief_summary>
	<brief_title>STEADFAST Long-Term Safety Extension</brief_title>
	<detailed_description>This multi-center , open-label , long-term safety extension study ACTIMMUNE® treatment Friedreich 's Ataxia ( FA ) child young adult . Participants complete 26 week treatment Week 28 Follow-Up Visit HZNP-ACT-302 ( NCT02593773 ) eligible enter long-term safety extension protocol . The Day 1 Visit study ( HZNP-ACT-303 ) occur day Week 28 Follow-Up Visit HZNP-ACT-302 ( NCT02593773 ) . Participants require return clinic visit least every six month . The treatment duration open-ended , treatment continue ACTIMMUNE® commercially available treatment FA United States Sponsor decides continue development treatment FA .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Written inform consent child assent , applicable . Completed 26 week treatment Week 28 FollowUp visit Study HZNPACT302 ( NCT02593773 ) . . If female , subject pregnant lactating intend become pregnant study , within 30 day last dose study drug . Female subject childbearing potential must negative urine pregnancy test result Week 26 Study HZNPACT302 ( NCT02593773 ) agree use reliable method contraception throughout study 30 day last dose study drug . If opinion Investigator , patient concomitant disease condition could interfere conduct study potentially put subject unacceptable risk , subject exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>27 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ACTIMMUNE</keyword>
	<keyword>interferon y-1b</keyword>
</DOC>